Ireland
--:--IST
Recruiting Observational

Clinical and CPET Parameters That Predict Improvement in Functional Capacity After TAVI

NCT06833762 · tracked via the Priya Life Science Spain tracker
Phase
Observational
Started
2025-01-01
Last updated
2026-09-02

Condition(s) studied

Aortic Stenosis Disease

Study summary

Determining Clinical and Cardiopulmonary exercise testing Parameters that may predict Improvement in Capacity After Transcatheter Aortic Valve Implantation

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All those patients ≥ 18 years of age with severe aortic stenosis approved for transfemoral TAVI. Both sexes, male and female will be included in the study. Exclusion Criteria: Very severe aortic stenosis, defined as a valve area of ≤0.6 cm2 , mean gradient ≥60 mmHg or Vmax \>5 m/s * Previous syncope * Proven exercise-induced arrhythmias * Previously known dynamic left ventricular outflow tract (LVOT) obstruction, defined as LVOT gradient of ≥ 30 mmHg by echocardiography * Concomitant coronary artery disease pending percutaneous coronary intervention * Inability to consent * Physical limitation to perform an exercise test * Non-elective procedure * Valve-in-valve procedure

Primary outcome measure(s)

  • Delta VO2 max and Delta VO2 at anaerobic threshold — CPET performed 2 weeks before TAVI and 4-6 weeks after
    Change in CPET parameters after Transcatheter Aortic valve implantation (TAVI): VO2 max, VO2 at anaerobic threshold
  • Clinical and functional pre-TAVI factors that predict improvement in functional capacity after TAVI — CPET performed 2 weeks before TAVI and 4-6 weeks after
    To identify clinical and functional pre-TAVI factors that predict improvement in functional capacity after TAVI (i.e., VO2 max increase \> 2.5 ml/kg/min or \>10% increase in VO2 max). ml/kg/min or \>10% increase in VO2 max).

Trial sites (1)

FacilityCityRegionStatus
Hospital Clinic Barcelona Barcelona Spain Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06833762 on ClinicalTrials.gov ↗ ← All trials in Spain